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Abstract
RNA polymerase (pol) III transcription is responsible for the transcription of small, untranslated RNAs involved in
fundamental metabolic processes such mRNA processing (U6 snRNA) and translation (tRNAs). RNA pol III
transcription contributes to the regulation of the biosynthetic capacity of a cell and a direct link exists between
cancer cell proliferation and deregulation of RNA pol III transcription. Accurate transcription by RNA pol III requires
TFIIIB, a known target of regulation by oncogenes and tumor suppressors. There have been significant advances in
our understanding of how TFIIIB-mediated transcription is deregulated in a variety of cancers. Recently, BRF2, a
component of TFIIIB required for gene external RNA pol III transcription, was identified as an oncogene in
squamous cell carcinomas of the lung through integrative genomic analysis. In this review, we focus on recent
advances demonstrating how BRF2-TFIIIB mediated transcription is regulated by tumor suppressors and oncogenes.
Additionally, we present novel data further confirming the role of BRF2 as an oncogene, extracted from the
Oncomine database, a cancer microarray database containing datasets derived from patient samples, providing
evidence that BRF2 has the potential to be used as a biomarker for patients at risk for metastasis. This data further
supports the idea that BRF2 may serve as a potential therapeutic target in a variety of cancers.
Introduction
Cancer is a major health problem afflicting millions of
Americans annually and despite tremendous research
and treatment advances, is still the leading cause of
death amongst men and women younger than age 85
years [1]. A dominant characteristic of many types of
cancer cells is its ability to proliferate uncontrollably.
RNA polymerase (pol) III contains the largest number
of subunits (17 subunits) and is responsible for the tran-
scription of small, less than 300 nucleotides, untrans-
l a t e dR N A si n v o l v e di nf u n d a m e n t a lm e t a b o l i c
processes, such as RNA processing (U6 snRNA) and
translation (tRNAs), which contribute to cell prolifera-
tion [2]. Thus, deregulation of RNA pol III transcription
can lead to aberrant production of critical RNAs contri-
buting to uncontrolled cell growth, a hallmark trait of
many types of cancer.
Like all eukaryotic polymerases, RNA pol III cannot
recognize its target promoters directly and accurate
initiation requires TFIIIB [2-4]. In higher eukaryotes,
thus far, two forms of TFIIIB have been identified [2-4].
BRF1-TFIIIB required for transcription by gene internal
RNA pol III promoters (tRNA) contains Bdp1, TBP and
BRF1 (Figure 1). BRF2-TFIIIB required for transcription
from RNA pol III gene external promoters contain
Bdp1, TBP and BRF2 (Figure 1) [2]. Examples of genes
transcribed by BRF2-TFIIIB include the human U6
snRNA gene involved in RNA splicing, the 7SK gene
whose RNA product has been demonstrated to nega-
tively regulate RNA Pol II transcription elongation by
binding to the elongation factor P-TEFb, the RNase
mitochondrial RNA processing (MRP) which partici-
pates in pre-rRNA processing, novel noncoding RNAs
of unknown function (reviewed in [2,5]).
BRF2 (TFIIB-related factor 2) shares structural fea-
tures with TFIIB and BRF1 (Figure 1B). TFIIB, BRF1
and BRF2 all contain N-terminal zinc ribbon domains,
core domains containing imperfect repeats; BRF1 and
BRF2 have unrelated C-terminal extensions (Figure 1B)
[2]. The C-terminus of BRF2 is required for association
with TBP and SNAPc (small nuclear activating protein
complex) on the U6 promoter [6].
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Many different transformed cell types have been shown
to have increased products of RNA pol III, when trans-
formed by DNA tumor viruses, as well as chemical car-
cinogens [7-11] and their relevance has been validated
in tumors of the breast, cervix, esophagus, lung, ovary,
parotid, and tongue, but not in corresponding normal
tissues tumors [12]. Specifically, RT-PCR analysis has
demonstrated that tRNAs are overproduced consistently
in human ovarian cancers [13]. Also, tRNA levels have
been shown to be 10-fold higher in breast cancer cells
than in normal cells [14]. These increases are not simply
a consequence of rapid cell proliferation in cancer [15],
but instead contribute to tumorigenesis, as it has been
demonstrated that overexpression of tRNAi
Met induces
proliferation and immortalization of fibroblasts [16].
Activation of TFIIIB activity has been noted in a vari-
ety of cancers types. Increased TBP expression has been
observed in a clinically significant number of human
colon cancers [17]. Also, overexpression of BRF1 has
also been shown to transform mouse embryo fibroblasts
[16]. Bdp1 is overexpressed in cells transformed by
papovaviruses [11], but changes in expression levels in
specific human cancer types have not been determined.
Amplification of BRF2 has been noted in breast cancer
[18,19] and more recently a human bladder cancer cell
line [20]. Recently, Lockwood et al. demonstrated that
genetic activation of BRF2 represents a unique mechan-
ism of squamous cell carcinoma tumorigenesis, also pro-
viding the first clinical evidence implicating BRF2 as a
novel lineage-specific oncogene in lung squamous cell
carcinoma [20]. This review will focus on BRF2-TFIIIB
activity in cancer.
Regulation of BRF2-TFIIIB activity by oncogenes
and tumor suppressors
RNA pol III transcription is tightly regulated during the
cell cycle to ensure normal cellular growth [21]. Cellular
levels of RNA pol III are specifically increased in tissues
isolated from mice with myeloma compared to tumor-
free mice [22], directly linking RNA pol III activity and
cancer. Recently, it was demonstrated that BRF1 and
TBP are capable of driving oncogenic transformation
[16,23]. These observations demonstrate that elevation
of RNA pol III transcription contributes to oncogenesis.
TFIIIB activity is strictly regulated by Maf1 [24-27], che-
mopreventative agents [28], and oncogenes and tumor
suppressors which are discussed below.
Figure 1 Gene internal and external TFIIIB. (A) Schematic of gene-internal TFIIIB (BRF1-TFIIIB) and gene-external human TFIIIB (BRF2-TFIIIB),
note the difference in complexes is BRF1 and BRF2. (B) Schematic representation of TFIIB, BRF1 and BRF2 protein structures. Note the unrelated
C-terminal extensions in the TFIIIB subunits BRF1 and BRF2. (Adapted from [2]).
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protein kinase with growth-promoting and oncogenic
properties. CK2 is abnormally active in a variety of
human cancers (Figure 2) [29]. It has been demon-
strated that CK2 interacts stably with TFIIIB; BRF1 is
phosphorylated in cells and CK2 inhibitors can decrease
this phosphorylation, thereby promoting transcription
complex assembly [29].
TFIIIB activity is targeted by tumor suppressors
[30-36] such as ARF [37], RB (Retinoblastoma protein)
[30,38], p53 [39-43] and BRCA1 (breast cancer suscept-
ibility gene 1) [44].
RB controls cell growth by preventing cell cycle entry
in the absence of appropriate mitogenic signals and
inactivation is associated with a variety of human can-
cers [45]. RB regulates RNA pol III transcription by dis-
rupting interactions between TFIIIB and RNA pol III
[38,46-49] RB-mediated repr e s s i o no fU 6t r a n s c r i p t i o n
can be restored by recombinant SNAPc and TBP [46].
p53 is activated in response to cellular stress, inducing
cell cycle arrest or apoptosis, and its inactivation is con-
sidered a critical step in carcinogenesis [50]. p53
represses not only Alu and U6 transcription, but also
tRNA, 5S rRNA, VAI, B2 and EBER (Epstein-Barr virus)
transcription, establishing p53 as a general repressor of
RNA pol III transcription [39]. p53 regulates U6 tran-
scription through interaction with the BRF2-TFIIIB sub-
unit TBP [41] and SNAPc [51].
BRCA1 plays a role in DNA repair, cell cycle regula-
tion, apoptosis, genome integrity and ubiquitination
[52,53]. Recently, BRCA1 has been characterized as a
general repressor of RNA pol III transcription [44].
BRF2 overexpression alleviates BRCA1 mediated repres-
sion of U6 transcription [44], suggesting that regulation
of U6 transcription by BRCA1 occurs, in part, through
BRF2. However, it is currently unclear whether the
observed inhibition of RNA pol III transcription is a
result of direct or indirect interactions between BRCA1
and BRF2, or BRCA1 and TFIIIB in general.
BRF2, a general oncogene?
It is established that RNA pol III is often deregulated in
cancers [33-35] and specific elevation of RNA pol III
transcripts and RNA pol III transcription factors such as
U6 snRNA and BRF2 is a feature of both transformed
cells and cancers [54]. Recently, Lockwood et al identi-
fied BRF2 as a novel oncogene in lung squamous cell
carcinoma demonstrating that overexpression of BRF2
can drive expression of RNA pol III transcripts contri-
buting to squamous cell carcinoma tumorigenesis [20].
However, it cannot currently be ruled out that TFIIIB,
particularly the BRF2 subunit, could bind and potentially
titrate tumor suppressors, thus alleviating some key
mechanisms normally keeping TFIIIB activity in check,
contributing to oncogenesis. Additionally, no Brf2-
dependent pol III transcript has yet been shown to have
transforming activity.
RNA pol III is a fundamental determinant of the capa-
city of a cell to grow and the identification of BRF2 as
an oncogene further demonstrates the importance of
proper regulation of RNA pol III transcription. Hence,
we queried the Oncomine database to systematically
assess gene expression levels of BRF2 in a variety of car-
cinomas. Oncomine is a bioinformatics initiative which
collects, standardizes, analyzes, and delivers cancer tran-
s c r i p t o m ed a t at ot h eb i o m e d ical research community
[55]. Rhodes et al. analysis of cancer transcriptome data
has identified the genes, pathways, and networks deregu-
lated across 18,000 cancer gene expression microarrays
spanning 35 cancer types (for a comprehensive overview
of the Oncomine database refer to [55]). Differential
expression analysis is an important feature of the Onco-
mine resource. A unique feature of the Oncomine data-
base is Oncomine automatically computes differential
Figure 2 BRF2-TFIIIB is a target of regulation by tumor suppressors and oncogenic products. Depiction of tumor suppressor and
oncogenic products involved in the regulation of BRF2-TFIIIB. The tumor suppressors, p53, RB and BRCA1 are depicted as red circles. The
oncogenic kinase CK2 is depicted by a green box and functions in regulating BRF2-TFIIIB. The stress related protein Maf1 is depicted by a
triangle and functions in inhibiting BRF2-TFIIIB.
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ing for simple query for individual gene expression.
Thus, using the Oncomine database, we performed a
disease summary for BRF2 (Figure 3) to determine if
BRF2 overexpression was significant in various carcino-
mas. Based on this analysis, we determined that in stu-
dies comparing cancer versus normal tissue, BRF2 is
highly overexpressed in datasets focused on gastric, kid-
ney and melanoma cancers. Please note that sample
number for each data set used in our BRF2 analysis is
noted, and data sets are named for author whose data
set has been analyzed. In Figure 3, overexpression
represented by ‘red cells’ and under expression repre-
sented by ‘blue cells’ is determined based on the gene
rank percentile. The outlier analysis, as demonstrated
in Figure 3, suggests that there are 50 analyses which
have a significant increase in BRF2 expression and 45
analyses which have a significant decrease in BRF2
expression. The outlier analyses represents a small sub-
population of samples within the datasets, hence, they
do not reflect the majority of samples. We speculate
that out of the 478 unique analyses, the 45 analyses
which have a significant decrease of BRF2 expression
demonstrates that BRF2 overexpression may not be uni-
versal to all cancer patients. The Oncomine database is
a compilation of gene expression studies performed
from clinically-based analyses performed on patient
samples. The 4 analyses which are significant out of 162
that are significant include gastric, kidney and mela-
noma cancer datasets (Figure 3). This criterion for this
specific BRF2 disease summary performed was stringent
as we required a p-value of 1E-4 and a fold-change of 2
for BRF2 gene expression compared to the controls.
Hence, we believe that due to the stringency of our cri-
terion, only 4 analyses showed a significant increase in
BRF2 expression.
Figure 3 Oncomine Analysis: Disease Summary for BRF2. The Oncomine database was queried for BRF2 expression in the available datasets
based on the following: cancer type, cancer versus normal, cancer versus cancer, cancer subtype, cancer versus baseline, pathway and drug and
outlier analyses. The ‘red cells’ represents BRF2 overexpression and the ‘blue cells’ represent BRF2 underexpression. The levels of expression are
based on the gene rank percentile. This disease summary was performed using a criterion of a 2 fold change for BRF2 expression and a p-value
of 1E-4. Using these stringent criteria for BRF2 expression analysis, we found that BRF2 is highly overexpressed in the following cancer vs normal
datasets: gastric, kidney and melanoma cancers. In the cancer vs cancer, multi-cancer datasets, BRF2 is overexpressed in leukemias and
lymphomas. The outlier analysis, which is used to determine significant BRF2 expression in a subset of the patient samples, showed that BRF2 is
both over- and under-expressed across the analyzed cancers. (Oncomine database).
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cant increase in BRF2 expression and as demonstrated
in Figure 4A, the Talantov Melanoma dataset, com-
prised of 70 patient samples shows a statistically signifi-
cant overexpression of BRF2 mRNA, p-value = 1.15E-
15, in cutaneous melanoma compared to normal skin.
Figure 4B shows a statistically significant overexpression
of BRF2 mRNA, p-value = 7.64E-5, in clear renal cell
carcinoma compared to normal kidney in the Gumz
Renal dataset, comprised of 20 patient samples. Lastly,
Figure 4C shows a statistically significant overexpression
of BRF2 mRNA, p-value = 5.35E-5, in the DErrico Gas-
tric diffuse gastric adenocarcinoma compared to gastric
mucosa dataset, comprised of 69 patient samples. Addi-
tionally, Lockwood et al have recently identified BRF2 as
an oncogene in lung squamous cell carcinoma [20]. To
determine if there was a correlation with BRF2 overex-
pression and lung carcinoma, we analyzed the Garber
Lung dataset, comprised of 73 patient samples, Figure
4D. The data retrieved from the Garber Lung study
shows a correlation between BRF2 overexpression and
an advanced N stage, N1, in lung carcinoma samples.
Figure 4 Oncomine analysis of BRF2 expression in gastric, kidney, melanoma and lung cancers. As seen in Figure 3, BRF2 is significantly
overexpressed in gastric, kidney and melanoma cancer datasets within the Oncomine datasets. We further queried Oncomine for each of these
specific cancers to compare the fold change of BRF2 expression in the cancerous tissue compared to the controls for each specific cancer. All p-
values represent a student’s t-test. Figure 4A shows that BRF2 is overexpressed in cutaneous melanomas compared to normal skin in the
Talantov Melanoma dataset [58]. BRF2 overexpression is significant with a p-value of 1.15E-15 and a total of 70 patient samples used for this
analysis. Figure 4B shows that BRF2 is overexpressed in clear cell renal carcinoma compared to normal kidney in the Gumz Renal dataset [59].
BRF2 overexpression is significant with a p-value of 7.64E-5 and a total of 20 patient samples were used for this analysis. Figure 4C shows that
BRF2 is overexpressed in diffuse gastric adenocarcinoma versus normal gastric mucosa in the DErrico Gastric dataset [60]. BRF2 overexpression is
significant with a p-value of 5.35E-5 and a total of 69 patient samples were used for this analysis. Lastly, Figure 4D shows that BRF2 is
overexpressed in advance N1+ stage lung adenocarcinoma compared to N0 stage in the Garber Lung Adenocarcinoma dataset [61]. BRF2
overexpression is significant with a p-value of 0.023 and a total of 73 patient samples were analyzed. (Oncomine database).
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culated as previously described [55].
Further query of the information presented in the
BRF2 disease summary demonstrated that in analyses
comparing multi-cancers, “cancer versus cancer”,B R F 2
is overexpressed in both leukemia and lymphoma as
well. In the case of BRF2 expression in leukemia, we
searched various leukemia datasets and found that
across 22 analyses, BRF2 was significantly overexpressed,
Figure 5A, p-value = 0.028. In the case of BRF2 expres-
sion in lymphoma, we found that across 4 analyses,
BRF2 was significantly overexpressed, Figure 5B, p-value
= 0.011.
Interestingly, analysis of the BRF2 disease summary
shows that BRF2 is highly expressed on the basis of out-
lier gene expression using a method called COPA (can-
cer outlier profile analysis). COPA was previously
described and utilized to identify oncogenic chromoso-
mal aberrations such as the TMPRSS2:ETS fusion gene
in prostate cancer by Tomlins et al [56]. Based on the
BRF2 disease summary, we focused on breast carcinoma
as this was most significant. Analysis of the 95% outlier
across 17 breast carcinoma analyses (Figure 6) shows
that BRF2 is highly overexpressed. This demonstrates
that in 5% of the samples analyzed in these specific stu-
dies, BRF2 overexpression is significant in a small sub-
population of samples.
Lastly, we investigated if there was a correlation
between BRF2 overexpression and clinical outcome.
Using breast carcinoma studies, we performed a meta-
analysis across 10 different breast carcinoma datasets
studying recurrence, metastasis and death, Figure 7A.
We determined that BRF2 overexpression did indeed
correlate with clinical outcome. Figure 7B represents
one dataset analyzed in Figure 7A, the vandeVijver
breast carcinoma study, and shows that BRF2 overex-
pression is highly significant in patients presenting with
metastasis at year 1, p-value = 0.034, and at year 5,
Figure 5 Oncomine analysis of BRF2 expression in leukemia and lymphoma. As demonstrated in Figure 3, BRF2 is overexpressed in both
leukemia and lymphoma, cancer vs cancer datasets. We further queried the Oncomine database to analyze BRF2 expression in both leukemia
and lymphoma. Figure 5A represents an analysis performed across 22 leukemia analyses found within Oncomine. The p-value, 0.028, represents a
student’s t-test measuring BRF2 overexpression in cancerous tissues, and the red represents significant overexpression. This analysis shows that
BRF2 is significantly overexpressed across leukemia. The table states the datasets analyzed and the number of patient samples used in each
study. Figure 5B represents an analysis performed across 4 lymphoma analyses found within Oncomine. The p-value, 0.011, represents a student’s
t-test measuring BRF2 overexpression in cancerous tissue and the red represents significant overexpression. This analysis shows that BRF2 is
significantly overexpressed across lymphoma. The table states the datasets used for analysis and the number of patient samples used in each
study. (Oncomine database).
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it shows promise for the potential use of BRF2 as a
potential biomarker for patients at risk for metastasis
and may serve as a potential therapeutic target.
Recently, RNA pol III transcription has been the focus
of a Phase I and pharmacokinetic study. Hammond-
Thelin et al. studied the effects of a novel nucleoside
analog inhibitor (TAS-106) of RNA pol I, II and III, in
patients with advanced solid malignancies [57]. Pre-
viously, TAS-106 has demonstrated antitumor activity in
various human cancer models including leukemic, lung,
colorectal, stomach, pancreatic, and gastric cancers [57].
The principal objectives of the study were to determine
the maximum tolerated dose in patients, characterize
the toxicities associated with TAS-106 administration,
determine the pharmacokinetics of TAS-106 and study
if there was any indication of antitumor activity in
patients [57]. Although this study is in its infancy, it’s
representative of the potential use of RNA pol III inhibi-
tors as a means of pharmacological target for the treat-
ment of cancers.
Conclusions
By elucidating the mechanism(s) by which RNA pol III
transcription is both regulated and deregulated, it will be
possible to further understand the mechanism(s) by
which aberrant activity of the general transcription
machinery contributes to cancer development. Deregula-
tion of RNA pol III transcription in cancers coupled with
the observation that TFIIIB, specifically BRF2-TFIIIB, is
commonly a target of deregulation in a variety of cancers
demonstrates that RNA pol III transcription is indeed a
key player in tumorigenesis and could serve as a novel
target in the development of pharmacological agents.
Figure 6 Oncomine analysis of BRF2 expression in breast carcinoma using COPA. As seen in Figure 3, BRF2 was overexpressed in a total of
50 analyses using an outlier analysis. COPA (cancer outlier profile analysis) analyzes a small subpopulation of samples which represent outliers
within the datasets for significant expression and does not represent the majority of samples. We investigated BRF2 expression in several breast
carcinoma studies based on the high number of analyses BRF2 was overexpressed in using COPA (Figure 3). Based on the COPA method, BRF2
is highly overexpressed across 17 breast carcinoma analyses in a subset of the patient samples used for each respective analysis. The red
represents significant overexpression. The datasets used for this analysis and the number of patient samples used in each individual study are
shown as well. (Oncomine database).
Cabarcas and Schramm Molecular Cancer 2011, 10:47
http://www.molecular-cancer.com/content/10/1/47
Page 7 of 10Acknowledgements
This work was supported in part by NIH grant 1R15CA133842-01A1 (LS). The
authors wish to apologize, due to space restrictions, that not all TFIIIB
studies could be mentioned. We thank Dr. Joby Jacob for his assistance with
figure preparation.
Author details
1National Cancer Institute, Laboratory of Cancer Prevention, Cancer Stem Cell
Section, 1050 Boyles Street, Building 560, Room 21-81, Frederick, MD 21702,
USA.
2Department of Biological Sciences, St. John’s University, Queens, New
York 11439, USA.
Authors’ contributions
SC reviewed the literature, wrote and drafted the manuscript; LS corrected
and finalized the manuscript. All authors read and approved the final
version.
Competing interests
The authors declare that they have no competing interests.
Received: 13 December 2010 Accepted: 25 April 2011
Published: 25 April 2011
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009.
CA Cancer J Clin 2009, 59(4):225-49.
2. Schramm L, Hernandez N: Recruitment of RNA polymerase III to its target
promoters. Genes Dev 2002, 16(20):2593-620.
3. Huang Y, Maraia RJ: Comparison of the RNA polymerase III transcription
machinery in Schizosaccharomyces pombe, Saccharomyces cerevisiae
and human. Nucleic Acids Res 2001, 29(13):2675-90.
4. Geiduschek EP, Kassavetis GA: The RNA polymerase III transcription
apparatus. J Mol Biol 2001, 310(1):1-26.
Figure 7 Oncomine analysis: BRF2 overexpression and clinical outcome. To determine if BRF2 overexpression correlated with patient
outcome in the clinic, we performed further analysis using Oncomine datasets focused on breast carcinoma studies analyzing patient death,
recurrence and metastasis. Figure 7A shows that BRF2 is overexpressed across 10 breast carcinoma analyses which focused on patient recurrence
at 3 and 5 years; metastasis at 1 and 5 years; and patient death at 3 and 5 years. The p-value, 0.034, represents a student’s t-test measuring BRF2
overexpression in the analyzed datasets and the red represents significant overexpression of BRF2. Overall, there is a correlation with BRF2
overexpression and death, recurrence and metastasis in patients diagnosed with breast carcinoma. The datasets used for this analysis and the
number of patient samples used in each individual study are shown as well. To further analyze BRF2 overexpression and the correlation with
metastasis, we used the vandeVijver breast carcinoma study, (295 patient samples analyzed). Figure 7B demonstrates that in patients presenting
with metastasis at 1 and 5 years, there is significant overexpression of BRF2, p-value 0.034 and 0.006 respectively, in comparison to patients with
no metastasis. (Oncomine database).
Cabarcas and Schramm Molecular Cancer 2011, 10:47
http://www.molecular-cancer.com/content/10/1/47
Page 8 of 105. Dieci G, Fiorino G, Castelnuovo M, Teichmann M, Pagano A: The expanding
RNA polymerase III transcriptome. Trends Genet 2007, 23(12):614-22.
6. Saxena A, Ma B, Schramm L, Hernandez N: Structure-function analysis of
the human TFIIB-related factor II protein reveals an essential role for the
C-terminal domain in RNA polymerase III transcription. Mol Cell Biol 2005,
25(21):9406-18.
7. Wang HD, Yuh CH, Dang CV, Johnson DL: The hepatitis B virus X protein
increases the cellular level of TATA-binding protein, which mediates
transactivation of RNA polymerase III genes. Mol Cell Biol 1995,
15(12):6720-8.
8. White RJ, Stott D, Rigby PW: Regulation of RNA polymerase III
transcription in response to Simian virus 40 transformation. Embo J 1990,
9(11):3713-21.
9. Gottesfeld JM, Johnson DL, Nyborg JK: Transcriptional activation of RNA
polymerase III-dependent genes by the human T-cell leukemia virus
type 1 tax protein. Mol Cell Biol 1996, 16(4):1777-85.
10. Larminie CG, Sutcliffe JE, Tosh K, Winter AG, Felton-Edkins ZA, White RJ:
Activation of RNA polymerase III transcription in cells transformed by
simian virus 40. Mol Cell Biol 1999, 19(7):4927-34.
11. Felton-Edkins ZA, White RJ: Multiple mechanisms contribute to the
activation of RNA polymerase III transcription in cells transformed by
papovaviruses. J Biol Chem 2002, 277(50):48182-91.
12. Chen W, Bocker W, Brosius J, Tiedge H: Expression of neural BC200 RNA in
human tumours. J Pathol 1997, 183(3):345-51.
13. Winter AG, Sourvinos G, Allison SJ, Tosh K, Scott PH, Spandidos DA,
White RJ: RNA polymerase III transcription factor TFIIIC2 is overexpressed
in ovarian tumors. Proc Natl Acad Sci USA 2000, 97(23):12619-24.
14. Pavon-Eternod M, Gomes S, Geslain R, Dai Q, Rosner MR, Pan T: tRNA over-
expression in breast cancer and functional consequences. Nucleic Acids
Res 2009, 37(21):7268-80.
15. Marshall L, White RJ: Non-coding RNA production by RNA polymerase III
is implicated in cancer. Nat Rev Cancer 2008, 8(12):911-4.
16. Marshall L, Kenneth NS, White RJ: Elevated tRNA(iMet) synthesis can drive
cell proliferation and oncogenic transformation. Cell 2008, 133(1):78-89.
17. Johnson SA, Dubeau L, Kawalek M, Dervan A, Schonthal AH, Dang CV,
Johnson DL: Increased expression of TATA-binding protein, the central
transcription factor, can contribute to oncogenesis. Mol Cell Biol 2003,
23(9):3043-51.
18. Melchor L, Garcia MJ, Honrado E, Pole JC, Alvarez S, Edwards PA, Caldas C,
Brenton JD, Benitez J: Genomic analysis of the 8p11-12 amplicon in
familial breast cancer. Int J Cancer 2007, 120(3):714-7.
19. Garcia MJ, Pole JC, Chin SF, Teschendorff A, Naderi A, Ozdag H, Vias M,
Kranjac T, Subkhankulova T, Paish C, Ellis I, Brenton JD, Edwards PA,
Caldas C: A 1 Mb minimal amplicon at 8p11-12 in breast cancer
identifies new candidate oncogenes. Oncogene 2005, 24(33):5235-45.
20. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J,
Williams AC, Hwang D, Zhu CQ, Buys TP, Yee J, English JC, Macaulay C,
Tsao MS, Gazdar AF, Minna JD, Lam S, Lam WL: Integrative Genomic
Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung
Squamous Cell Carcinoma. PLoS Med 2010, 7(7):e1000315.
21. Scott PH, Cairns CA, Sutcliffe JE, Alzuherri HM, McLees A, Winter AG,
White RJ: Regulation of RNA polymerase III transcription during cell cycle
entry. J Biol Chem 2001, 276(2):1005-14.
22. Schwartz LB, Sklar VE, Jaehning JA, Weinmann R, Roeder RG: Isolation and
partial characterization of the multiple forms of deoxyribonucleic acid-
dependent ribonucleic acid polymerase in the mouse myeloma, MOPC
315. J Biol Chem 1974, 249(18):5889-97.
23. Johnson SA, Dubeau L, Johnson DL: Enhanced RNA polymerase III-
dependent transcription is required for oncogenic transformation. J Biol
Chem 2008, 283(28):19184-91.
24. Johnson SS, Zhang C, Fromm J, Willis IM, Johnson DL: Mammalian Maf1 is
a negative regulator of transcription by all three nuclear RNA
polymerases. Mol Cell 2007, 26(3):367-79.
25. Reina JH, Azzouz TN, Hernandez N: Maf1, a New Player in the Regulation
of Human RNA Polymerase III Transcription. PLoS ONE 2006, 1:e134.
26. Rollins J, Veras I, Cabarcas S, Willis I, Schramm L: Human Maf1 negatively
regulates RNA polymerase III transcription via the TFIIB family members
Brf1 and Brf2. Int J Biol Sci 2007, 3(5):292-302.
27. Goodfellow SJ, Graham EL, Kantidakis T, Marshall L, Coppins BA, Oficjalska-
Pham D, Gerard M, Lefebvre O, White RJ: Regulation of RNA Polymerase III
Transcription by Maf1 in Mammalian Cells. J Mol Biol 2008.
28. Jacob J, Cabarcas S, Veras I, Zaveri N, Schramm L: The green tea
component EGCG inhibits RNA polymerase III transcription. Biochem
Biophys Res Commun 2007, 360(4):778-83.
29. Johnston IM, Allison SJ, Morton JP, Schramm L, Scott PH, White RJ: CK2
forms a stable complex with TFIIIB and activates RNA polymerase III
transcription in human cells. Mol Cell Biol 2002, 22(11):3757-68.
30. Felton-Edkins ZA, Kenneth NS, Brown TR, Daly NL, Gomez-Roman N,
Grandori C, Eisenman RN, White RJ: Direct regulation of RNA polymerase
III transcription by RB, p53 and c-Myc. Cell Cycle 2003, 2(3):181-4.
31. Marshall L, White RJ: Non-coding RNA production by RNA polymerase III
is implicated in cancer. Nat Rev Cancer 2008.
32. Mauger E, Scott PH: Mitogenic stimulation of transcription by RNA
polymerase III. Biochem Soc Trans 2004, 32(Pt 6):976-7.
33. White RJ: RNA polymerase III transcription–a battleground for tumour
suppressors and oncogenes. Eur J Cancer 2004, 40(1):21-7.
34. White RJ: RNA polymerase III transcription and cancer. Oncogene 2004,
23(18):3208-16.
35. White RJ: RNA polymerases I and III, growth control and cancer. Nat Rev
Mol Cell Biol 2005, 6(1):69-78.
36. White RJ: RNA polymerases I and III, non-coding RNAs and cancer. Trends
Genet 2008.
37. Morton JP, Kantidakis T, White RJ: RNA polymerase III transcription is
repressed in response to the tumour suppressor ARF. Nucleic Acids Res
2007, 35(9):3046-52.
38. Chu WM, Wang Z, Roeder RG, Schmid CW: RNA polymerase III
transcription repressed by Rb through its interactions with TFIIIB and
TFIIIC2. J Biol Chem 1997, 272(23):14755-61.
39. Cairns CA, White RJ: p53 is a general repressor of RNA polymerase III
transcription. Embo J 1998, 17(11):3112-23.
40. Chesnokov I, Chu WM, Botchan MR, Schmid CW: p53 inhibits RNA
polymerase III-directed transcription in a promoter-dependent manner.
Mol Cell Biol 1996, 16(12):7084-8.
41. Crighton D, Woiwode A, Zhang C, Mandavia N, Morton JP, Warnock LJ,
Milner J, White RJ, Johnson DL: p53 represses RNA polymerase III
transcription by targeting TBP and inhibiting promoter occupancy by
TFIIIB. Embo J 2003, 22(11):2810-20.
42. Stein T, Crighton D, Boyle JM, Varley JM, White RJ: RNA polymerase III
transcription can be derepressed by oncogenes or mutations that
compromise p53 function in tumours and Li-Fraumeni syndrome.
Oncogene 2002, 21(19):2961-70.
43. Stein T, Crighton D, Warnock LJ, Milner J, White RJ: Several regions of p53
are involved in repression of RNA polymerase III transcription. Oncogene
2002, 21(36):5540-7.
44. Veras I, Rosen EM, Schramm L: Inhibition of RNA Polymerase III
Transcription by BRCA1. Journal of Molecular Biology 2009, 387(3):523-531.
45. Burkhart DL, Sage J: Cellular mechanisms of tumour suppression by the
retinoblastoma gene. Nat Rev Cancer 2008, 8(9):671-82.
46. Hirsch HA, Gu L, Henry RW: The retinoblastoma tumor suppressor protein
targets distinct general transcription factors to regulate RNA polymerase
III gene expression. Mol Cell Biol 2000, 20(24):9182-91.
47. Larminie CG, Cairns CA, Mital R, Martin K, Kouzarides T, Jackson SP,
White RJ: Mechanistic analysis of RNA polymerase III regulation by the
retinoblastoma protein. Embo J 1997, 16(8):2061-71.
48. Sutcliffe JE, Brown TR, Allison SJ, Scott PH, White RJ: Retinoblastoma
protein disrupts interactions required for RNA polymerase III
transcription. Mol Cell Biol 2000, 20(24):9192-202.
49. White RJ, Trouche D, Martin K, Jackson SP, Kouzarides T: Repression of RNA
polymerase III transcription by the retinoblastoma protein. Nature 1996,
382(6586):88-90.
50. Kruse JP, Gu W: Modes of p53 regulation. Cell 2009, 137(4):609-22.
51. Gridasova AA, Henry RW: The p53 Tumor Suppressor Protein Represses
Human snRNA Gene Transcription by RNA Polymerases II and III
Independently of Sequence-Specific DNA Binding. Mol Cell Biol 2005,
25(8):3247-3260.
52. Billack B, Monteiro AN: BRCA1 in breast and ovarian cancer
predisposition. Cancer Lett 2005, 227(1):1-7.
53. Deng CX: BRCA1: cell cycle checkpoint, genetic instability, DNA damage
response and cancer evolution. Nucleic Acids Res 2006, 34(5):1416-26.
54. Cabarcas S, Jacob J, Veras I, Schramm L: Differential expression of the
TFIIIB subunits Brf1 and Brf2 in cancer cells. BMC Mol Biol 2008, 9:74.
Cabarcas and Schramm Molecular Cancer 2011, 10:47
http://www.molecular-cancer.com/content/10/1/47
Page 9 of 1055. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J,
Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S,
Ghosh D, Chinnaiyan AM: Oncomine 3.0: genes, pathways, and networks
in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007,
9(2):166-80.
56. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V,
Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF:
Characterization of a breast cancer cell line derived from a germ-line
BRCA1 mutation carrier. Cancer Res 1998, 58(15):3237-42.
57. Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y,
Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A, Rowinsky EK:
Phase I and pharmacokinetic study of 3’-C-ethynylcytidine (TAS-106), an
inhibitor of RNA polymerase I, II and III, in patients with advanced solid
malignancies. Invest New Drugs 2010.
58. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D,
Wang Y: Novel genes associated with malignant melanoma but not
benign melanocytic lesions. Clin Cancer Res 2005, 11(20):7234-42.
59. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ,
Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA:
Secreted frizzled-related protein 1 loss contributes to tumor phenotype
of clear cell renal cell carcinoma. Clin Cancer Res 2007, 13(16):4740-9.
60. D’Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F,
Saieva C, Ottini L, Palli D, Palombo F, Giuliani A, Dogliotti E: Genome-wide
expression profile of sporadic gastric cancers with microsatellite
instability. Eur J Cancer 2009, 45(3):461-9.
61. Kickhoefer VA, Searles RP, Kedersha NL, Garber ME, Johnson DL, Rome LH:
Vault ribonucleoprotein particles from rat and bullfrog contain a related
small RNA that is transcribed by RNA polymerase III. J Biol Chem 1993,
268(11):7868-73.
doi:10.1186/1476-4598-10-47
Cite this article as: Cabarcas and Schramm: RNA polymerase III
transcription in cancer: the BRF2 connection. Molecular Cancer 2011
10:47.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cabarcas and Schramm Molecular Cancer 2011, 10:47
http://www.molecular-cancer.com/content/10/1/47
Page 10 of 10